Sweden-based Elekta has secured CE mark approval for its Unity magnetic resonance radiation therapy (MR/RT) system.

ElektaUnity

Image: Elekta Unity magnetic resonance radiation therapy system. Photo: courtesy of PRNewsfoto/Elekta.

Claimed to be the world’s first high-field MR-linac, Elekta Unity enables to deliver radiation dose while simultaneously visualizing the tumor and surrounding healthy tissue with high- quality MR images.

Elekta Unity incorporates advanced tools that enable clinicians to adjust the patient’s treatment to the current anatomical information.

The Unity also incorporates advanced tools, which enables clinicians to adjust the patient’s treatment to this current anatomical information.

Elekta president and CEO Richard Hausmann said: “Receiving CE mark for Unity is a big achievement in revolutionizing the field of radiation therapy and a real watershed moment for treating cancer.

“The change that MR/RT will bring in cancer therapy is paramount in advancing patient treatment. I’m thankful to the MR-linac Consortium members, Philips (our MR technology partner) and our dedicated employees for helping us reach this important day.”

Unity deploys a premium high-field diagnostic-quality (1.5 Tesla) MRI that offers better image clarity, enabling to provide optimal care for each patient based on individual tumor characteristics.

The new system incorporates MR imaging and linear accelerator technologies, as well as advanced treatment planning into a single platform, helping clinicians to view and track difficult-to-visualize soft tissue anatomies while radiation dose is being delivered.

The system allows clinicians to view and track the target during treatment and respond accordingly, personalizing therapy for each patient every time they are treated.

University Medical Center (UMC) Utrecht department of radiotherapy’s experimental clinical physics professor Dr Bas Raaymakers said: “Unity is a tremendous innovation in patient care, one that enables a scan-plan-treat approach to developing tailored regimens that should yield substantive clinical benefits.”

Based in Stockholm of Sweden, Elekta is engaged in the development of advanced equipment and software to help treat patients with cancer and brain disorders.

The firm’s treatment solutions and oncology informatics portfolios are designed to advance the delivery of radiation therapy, radiosurgery and brachytherapy.